Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Endothelial Graft Rejection”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Post-approval studies (Phase 4)Study completedNCT01028443
What this trial is testing

Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

Who this might be right for
Endothelial Graft Rejection
Shahid Beheshti University of Medical Sciences
Post-approval studies (Phase 4)Study completedNCT05136443
What this trial is testing

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

Who this might be right for
Corneal Endothelial DystrophyCorneal Edema
Price Vision Group 70
Not applicableStudy completedNCT06101017
What this trial is testing

Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease

Who this might be right for
Corneal DiseaseEndothelial Corneal DystrophyCorneal Transplant Failure+1 more
Nitin Vaswani 19
Not applicableStudy completedNCT00810472
What this trial is testing

Functional Antigen Matching in Corneal Transplantation

Who this might be right for
Corneal Diseases
University Hospital Freiburg 650
Testing effectiveness (Phase 2)Study completedNCT01448213
What this trial is testing

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

Who this might be right for
Fuchs' DystrophyBullous Keratopathy
Price Vision Group 264